Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Grants Fast-Track Designation to Lilly & AstraZeneca’s Alzheimer’s Treatment

By Ryan Bushey | August 23, 2016

Eli Lilly and AstraZeneca gained an advantage in the race to develop a BACE inhibitor to treat Alzheimer’s.

The Food and Drug Administration provided a fast-track review for AZD3293, an oral beta secretase cleaving enzyme inhibitor (BACE) presently in Phase 3 clinical trials focusing on an early Alzheimer’s population, according to an announcement from both companies.

“The Fast Track designation in the U.S. for this promising potential therapy reinforces the ambition of the AstraZeneca-Lilly BACE alliance to help advance science for patients and their families managing this devastating illness,” said Craig Shering, AZD3293 Project Lead in Global Medicines Development at AstraZeneca. “BACE inhibitors have the potential to transform the treatment of Alzheimer’s disease, one of the biggest challenges facing medical science today.”

Studies so far have shown this class of drugs is capable of reducing amyloid beta levels found in the cerebro-spinal fluid of healthy volunteers and people with Alzheimer’s.

Eli Lilly entered this partnership with AstraZeneca in 2014 after the company ended its own BACE program due to liver toxicity issues, reported FierceBiotech. Lilly serves as the lead for clinical development while AstraZeneca will take charge of manufacturing. Commercialization responsibilities will fall under both organizations’ oversight along with sharing all future costs associated with this process.  

Data for the molecule’s final primary outcome in the first trial won’t arrive until August 2019. Both firms will kick-start a second placebo-controlled Phase 3 trial in the third quarter of 2016 targeting a mild Alzheimer’s dementia. The primary outcome for this particular trial would focus on cognitive change, which is believed to be a predictor for functional decline.

A fast-track designation guarantees these collaborators enter an expedited process for reviewing potent new therapies.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE